<DOC>
	<DOCNO>NCT02059590</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics 14C-labeled cleavage product ( BAL8728 ) , particular route excretion extent ot metabolism cleavage product follow administration single intravenous dose pyridinylmethyl-14C-labeled prodrug isavuconazonium sulfate ( BAL8557 ) . In addition , identify metabolic profile BAL8728 human plasma , urine and/or feces single intravenous dose pyridinylmethyl-14C-labeled BAL8557 evaluate pharmacokinetics BAL8728 BAL4815 . Safety tolerability single intravenous dose pyridinylmethyl-14C-labeled isavuconazonium sulfate also evaluate .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics BAL8728 After Single Dose Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>The subject body weight least 45 kg body mass index 18 32 kg/m2 , inclusive . The subject 's 12lead electrocardiogram ( ECG ) normal Screening Day 1 ; , abnormal , abnormality clinically significant . The ECG subject QTcF least 360 430 msec . The subject clinically significant disease history follow system : pulmonary , gastrointestinal , cardiovascular ( include history clinically significant arrhythmia ) , hepatic , neurological , psychiatric , renal , genitourinary , endocrine , metabolic , dermatologic , immunologic , hematologic , malignancy exclude non melanoma skin cancer . The subject positive test hepatitis B surface antigen hepatitis C antibodies Screening know positive human immunodeficiency virus . The subject know suspect allergy azole class compound , history multiple and/or severe allergy drug food history severe anaphylactic reaction . The subject use tobacco nicotine containing product last 6 month prior Day 1 . The subject treatment prescription drug , overthecounter medication , complementary alternative medicine within 14 day prior Day 1 , exception occasional use acetaminophen 2 g/day . The subject participate interventional clinical study receive investigational agent within 28 day 5 halflives , whichever longer , prior Screening . The subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission Day 1 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>14C-labeled isavuconazonium sulfate</keyword>
	<keyword>Pyridinylmethyl-14C-labeled isavuconazonium sulfate</keyword>
	<keyword>Healthy Subjects</keyword>
	<keyword>BAL8728</keyword>
	<keyword>BAL4815</keyword>
</DOC>